This article provides clinical guidance on decision-making and risk assessment for prescribing psychotropic medications during pregnancy and lactation.
Case report of 70-hour coma due to clozapine intoxication, highlighting the risk of severe sedation and the need for careful dose titration and monitoring.
This article discusses the clinical challenge of balancing teratogenic risks against the risk of psychiatric relapse when prescribing psychotropic medications during pregnancy.
This article examines trends in psychotropic medication prescribing patterns across various medical providers from 2016 to 2019, offering insights into the distribution of psychiatric pharmacotherapy in general practice.
This systematic review of 122 studies finds that most demographic and clinical variables do not reliably predict antidepressant response to ketamine or esketamine, with only early response and family history of substance use disorders showing promise for future investigation.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 12 – May 17)
- Consider a single 25 mg dose of psilocybin as a potential rapid-acting intervention for depression, noting that clinical symptom reductions can occur within 48 hours.
- Recognize that early response to ketamine or esketamine and a family history of substance use disorders are the only reliable predictors of antidepressant response identified in recent systematic reviews.
- Reassure pregnant patients that current meta-analyses indicate no causal link between antidepressant use during pregnancy and neurodevelopmental disorders in offspring.
- Exercise extreme caution with clozapine dosing and titration to prevent severe sedation and coma, as highlighted by recent case reports of intoxication.
- Balance the teratogenic risks of psychotropic medications against the significant risk of psychiatric relapse when making prescribing decisions during pregnancy.
- Acknowledge that psilocybin has demonstrated sustained antidepressant effects for over three months following a single dose in clinical trials.
- Evaluate psilocybin as a novel pharmacological option for treatment-resistant mood disorders, given evidence of rapid remission in Phase 2 trials.
- Utilize new clozapine guidelines to inform risk assessment and management strategies for patients prescribed this high-risk antipsychotic.
- Monitor prescribing patterns across general practice settings to understand the broader distribution and context of psychiatric pharmacotherapy in your patient population.
Diagnosis & Treatment 2
A meta-analysis indicates no causal link between antidepressant use during pregnancy and neurodevelopmental disorders, providing reassurance for prescribing decisions in pregnant patients.
A meta-analysis indicates no causal link between antidepressant use during pregnancy and neurodevelopmental disorders, providing reassurance for prescribing decisions in pregnant patients.
Clinical Pearl 1
A randomized clinical trial demonstrates that a single 25 mg dose of psilocybin produces rapid, clinically meaningful symptom reductions for depression within 48 hours, suggesting a potential alternative to daily antidepressants.
Journal Article 1
This Psychology Today article reviews psilocybin clinical trials for palliative and end-of-life care, but as a general interest publication rather than a primary source or rigorous clinical report, it lacks specific prescribing data or FDA context for immediate clinical application.
Policy & Regulation 1
This article highlights a new clozapine guideline, which is directly relevant to psychiatric prescribing, alongside unrelated topics on paternal health and obesity.
Drug Development 1
A Phase 2 trial demonstrates that a single dose of psilocybin provides rapid relief of depression symptoms, supporting its potential as a rapid-acting antidepressant therapy.